Obio Pharmaceutical Holdings Ltd. has issued a release detailing the progress of its current crop of drug candidates. The company, which claims a focus on diabetes and influenza, reports that it has six drugs in development, two of them patented. The company plans to develop these drugs and then partner them with larger companies to bring them to market. Obio is headquartered in Hong Kong, but its research facilities are in Beijing. It also outsources some of its R&D work to outside groups. More details...